Psallidas et al reported 2 scores for the PROMISE study, one clinical and one biochemical. Both can stratify patients with a malignant pleural effusion. The authors are from multiple institutions in Europe, Russia and the United States.
Patient selection: malignant pleural effusion
Outcome: 3-month mortality
Differences between the clinical and biological scores:
(1) tissue inhibitor of metalloproteinase 1 (TIMP1)
(2) different weightings for the other parameters
Parameters for the clinical score:
(1) chemotherapy
(2) radiotherapy
(3) hemoglobin in g/dL
(4) white blood cell count in 10^9/L
(5) C-reactive protein nmol/L
(6) ECOG performance status
(7) cancer type
Parameter |
Finding |
Points |
chemotherapy |
no |
0 |
|
yes |
4 |
radiotherapy |
no |
0 |
|
yes |
2 |
hemoglobin |
> 16 g/dL |
0 |
|
14 to 16 |
1 |
|
12 to 14 |
2 |
|
10 to 12 |
3 |
|
< 10 g/dL |
4 |
WBC count |
< 4 * 10^9/L |
0 |
|
4 to 6.3 |
2 |
|
6.3 to 10 |
4 |
|
10 to 15.8 |
7 |
|
> 15.8 * 10^9/L |
10 |
C-reactive protein |
< 3 nmol/L |
0 |
|
3 to 10 |
3 |
|
10 to 32 |
5 |
|
32 to 100 |
8 |
|
> 100 |
11 |
ECOG performance |
0 or 1 |
0 |
|
2 to 4 |
7 |
cancer type |
mesothelioma |
0 |
|
lung |
5 |
|
other |
4 |
where:
• The apparent SIU for CRP is nmol/L. 1 nmol/L = 0.105 mg/L if the molecular weight is taken as 105,000 Daltons. However, higher molecular weights (up to 144,000) are given.
total score =
= SUM(points for all 7 parameters)
Interpretation:
• minimum score: 0
• maximum score: 43
• The higher the score the worse the prognosis.
Clinical Score |
Group |
3-Month Mortality |
0 to 20 |
A |
< 25% |
21 to 27 |
B |
25 to 49.9% |
28 to 35 |
C |
50 to 74.9% |
36 to 43 |
D |
75 to 100% |
Score |
Absolute Risk |
0 |
1.9 |
1 |
2.2 |
2 |
2.5 |
3 |
2.9 |
4 |
3.3 |
5 |
3.8 |
6 |
4.4 |
7 |
5 |
8 |
5.7 |
9 |
6.5 |
10 |
7.5 |
11 |
8.5 |
12 |
9.7 |
13 |
11 |
14 |
12.4 |
15 |
14 |
16 |
15.8 |
17 |
17.8 |
18 |
20 |
19 |
22.3 |
20 |
24.9 |
21 |
27.6 |
22 |
30.5 |
23 |
33.6 |
24 |
36.8 |
25 |
40.1 |
26 |
43.5 |
27 |
47 |
28 |
50.6 |
29 |
54.1 |
30 |
57.6 |
31 |
61 |
32 |
64.3 |
33 |
67.4 |
34 |
70.5 |
35 |
73.3 |
36 |
76 |
37 |
78.5 |
38 |
80.7 |
39 |
82.8 |
40 |
84.8 |
41 |
86.5 |
42 |
88.1 |
43 |
89.5 |
from the Appendix
Performance:
• The area under the ROC curve was 0.78.
Purpose: To evaluate a patient with a malignant pleural effusion the clinical PROMISE score.
Specialty: Hematology Oncology, Pulmonology
Objective: clinical diagnosis, including family history for genetics
ICD-10: C78.2,